Amifostine: A radioprotector in locally advanced head and neck tumors

Oncology Reports

Volumn 5, Issue 5, 1998, Pages 1255-1257

  Wagner, Wolfgang ^a   Prott, Franz Josef ^b   Schönekäs, Klaus Gregor ^a  

^a Paracelsus Klinik Osnabruck   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Amifostine; Head and neck cancer; Radiotherapy; Side effects

Indexed keywords

AMIFOSTINE; RADIOPROTECTIVE AGENT;

ADULT; ARTICLE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DYSPHAGIA; HEAD AND NECK TUMOR; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MUCOSA INFLAMMATION; NAUSEA; PRIORITY JOURNAL; RADIATION DERMATITIS; RADIATION PROTECTION; VOMITING; XEROSTOMIA;

EID: 0031875377     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.5.5.1255     Document Type: Article

References (13)

1. Franzen L, Funegard U, Ericson T and Henriksson R: Parotid gland function during and following radiotherapy of malignancies in the head and neck. Eur J Cancer 28: 457-462, 1992.
2. Kaplan P: Mantle irradiation of the major salivary glands. J Prosthet Dent 54: 681-686, 1985.
3. Dörr W, Dölling-Jochem I, Baumann M and Herrmann TH: Therapeutische Beeinflussung der radiogenen oralen Mukositis. Strahlenther Onkol 173: 183-192, 1997.
4. Capizzi RL, Scheffler BJ and Schein PS: Amifostine-mediated protection of normal bone marrow from cytotoxic chemotherapy. Cancer 72: 3495-3501, 1993.
5. Yuhas JM: Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2(3-amino-propylamino)-ethylphorothioic acid. Cancer Res 40: 1519-1524, 1980.
6. Treskes M, Nijtmans LGJ, Fichtlinger-Schepman AMJ, et al: The modulating agent WR-2721 and its main metabolites on the formation and stability of cisplatin-DNA adducts in vitro in comparison to the effects of thiosulphate and diethyldithiocarbamate. Biochem Pharmacol 43: 1013-1019, 1992.
7. Phillips TL: Sensitizers and protectors in clinical oncology. Semin Oncol 8: 65-82, 1981.
8. Eilers J, Berger AM and Petersen MC: Development, testing, and application of the oral assessment guide. Eilers Vol 15: 325, 1988.
9. McDonald S, Meyerowitz C, Smudzin T and Rubin P: Preliminary results of a pilot study using WR-2721 before fractionated irradiation of the head and neck to reduce salivary gland dysfunction. Int J Radiat Oncol Biol Phys 29: 747-754, 1994.
10. Wassermann TH: Radiotherapeutic studies with amifostine (ETHYOL). Semm Oncol 21 (Suppl. 11): 21-25, 1994.
11. Bohuslavizki KH, Brenner W, Lassmann S, Kaiser K, Tinnerneyer S, Meester J, Clausen M and Henze E: Protection of salivary glands by amifostine in patients treated with high dose radioiodine. Eur J Cancer 33: 59, 1997.
12. Füller J, Trog D, Koscielny S, Wendt TH and Beleites E: Toxizitat der Radiochemotherapie mit prolongierter 5-FU-Dauerinfusion bei inoperablen Tumoren der Kopf-Hals-Region unter Einsatz des Zytoprotektivums Amifostin. Strahlenther Onkol 173: 646, 1997.
13. Strnad V, Brizel D, Wannenmacher M and Sauer R: Phase-III Studie: Strahlentherapie ± WR-2721 bei Patienten mit HNO-Tumoren - vorläufige Ergebnisse. Strahlenther Onkol 173: 561, 1997.